
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

NICE has announced draft guidance for Ipsen’s cancer drug Cabometyx (cabozantinib), revealing it does not recommend the drug for use on …

Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

